Antibody-Based Immunotherapy And Targeted Immune Activation

Antibody-based immunotherapy uses monoclonal antibodies and antibody derivatives to target selected immune response components in cancer treatment^[1]. It includes immune checkpoint inhibitors, antigen-targeted antibodies, antibody-drug conjugates, and bispecific T-cell engagers^[1]. The field moved from conventional antibody targeting toward active immune redirection because T-cell activation and inhibition of suppressive immune mechanisms are now central therapeutic goals^[1][2].

Targeted immune activation works by blocking inhibitory immune checkpoints or physically linking immune effector cells to tumor cells^[2][3]. CTLA-4, PD-1, and PD-L1 are widely studied immune checkpoint targets, and antibodies against these pathways restore antitumor immune activity by interfering with suppressive signaling^[2][3]. Ipilimumab improved overall survival in previously treated metastatic melanoma, showing that checkpoint blockade can produce clinically meaningful immune activation^[3]. Blinatumomab redirects CD3-positive T cells against CD19-positive leukemia cells and produced longer overall survival than chemotherapy in advanced acute lymphoblastic leukemia^[4].

Antibody-drug conjugates extend targeted therapy by coupling antibody recognition to cytotoxic payload delivery^[1][5]. Trastuzumab deruxtecan showed durable antitumor activity in previously treated HER2-positive metastatic breast cancer, supporting HER2-directed antibody-drug conjugates as a major disease application^[5]. Bispecific antibodies recognize two antigens or epitopes and can combine immune-cell engagement, checkpoint inhibition, or non-checkpoint targeting in one engineered molecule^[6][7]. These formats are being evaluated in hematologic malignancies, breast cancer, melanoma, and treatment-resistant solid tumors^[1][5][6][7].

Current gaps include resistance, immune-related adverse events, on-target/off-tumor activity, and uncertainty over optimal target pairing^[6][7][8]. Bispecific strategies that target PD-L1 and TGF-β address two immunosuppressive pathways that contribute to cancer immune evasion^[8]. Future development should prioritize biomarker-guided patient selection, safer immune activation, rational antibody engineering, and combination regimens that preserve antitumor efficacy while limiting toxicity^[6][7][8].